|Aberrant endoplasmic reticulum stress in vascular smooth muscle increases vascular contractility and blood pressure in mice deficient of AMP-activated protein kinase-α2 in vivo.|
|PMID: 23288166 Owner: NLM Status: MEDLINE|
|OBJECTIVE: The endoplasmic reticulum (ER) plays a critical role in ensuring proper folding of newly synthesized proteins. Aberrant ER stress is reported to play a causal role in cardiovascular diseases. However, the effects of ER stress on vascular smooth muscle contractility and blood pressure remain unknown. The aim of this study was to investigate whether aberrant ER stress causes abnormal vasoconstriction and consequent high blood pressure in mice.
METHODS AND RESULTS: ER stress markers, vascular smooth muscle contractility, and blood pressure were monitored in mice. Incubation of isolated aortic rings with tunicamycin or MG132, 2 structurally unrelated ER stress inducers, significantly increased both phenylephrine-induced vasoconstriction and the phosphorylation of myosin light chain (Thr18/Ser19), both of which were abrogated by pretreatment with chemical chaperones or 5-Aminoimidazole-4-carboxamide ribonucleotide and metformin, 2 potent activators for the AMP-activated protein kinase. Consistently, administration of tauroursodeoxycholic acid or 4-phenyl butyric acid, 2 structurally unrelated chemical chaperones, in AMP-activated protein kinase-α2 knockout mice lowered blood pressure and abolished abnormal vasoconstrictor response of AMP-activated protein kinase-α2 knockout mice to phenylephrine. Consistently, tunicamycin (0.01 μg/g per day) infusion markedly increased both systolic and diastolic blood pressure, both of which were ablated by coadministration of 4-phenyl butyric acid. Furthermore, 4-phenyl butyric acid or tauroursodeoxycholic acid, which suppressed angiotensin II infusion-induced ER stress markers in vivo, markedly lowered blood pressure in angiotensin II-infused mice in vivo.
CONCLUSIONS: We conclude that ER stress increases vascular smooth muscle contractility resulting in high blood pressure, and AMP-activated protein kinase activation mitigates high blood pressure through the suppression of ER stress in vivo.
|Bin Liang; Shuangxi Wang; Qilong Wang; Wencheng Zhang; Benoit Viollet; Yi Zhu; Ming-Hui Zou|
Related Documents :
|24110256 - Monitoring of peripheral vascular condition using a log-linearized arterial viscoelasti...
24559466 - Computational study of the stability of the miniproteins trp-cage and gb1 beta-hairpin,...
25098026 - Effect of taurocholic acid on fetoplacental arterial pressures in a dual perfusion plac...
844016 - Pheochromocytoma presenting with pulmonary edema and hyperamylasemia.
17705736 - Improving tactile sensation in minimally invasive pediatric surgery.
9018516 - Greater airway narrowing in immature than in mature rabbits during methacholine challenge.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2013-01-03|
|Title: Arteriosclerosis, thrombosis, and vascular biology Volume: 33 ISSN: 1524-4636 ISO Abbreviation: Arterioscler. Thromb. Vasc. Biol. Publication Date: 2013 Mar|
|Created Date: 2013-02-14 Completed Date: 2013-04-10 Revised Date: 2013-08-30|
Medline Journal Info:
|Nlm Unique ID: 9505803 Medline TA: Arterioscler Thromb Vasc Biol Country: United States|
|Languages: eng Pagination: 595-604 Citation Subset: IM|
|Section of Molecular Medicine, Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.|
|APA/MLA Format Download EndNote Download BibTex|
AMP-Activated Protein Kinases
Aminoimidazole Carboxamide / analogs & derivatives, pharmacology
Antihypertensive Agents / pharmacology
Blood Pressure* / drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Endoplasmic Reticulum Stress* / drug effects
Enzyme Activators / pharmacology
Hypertension / chemically induced, enzymology*, physiopathology, prevention & control
Leupeptins / pharmacology
Muscle, Smooth, Vascular / drug effects, enzymology*
Myosin Light Chains / metabolism
Nitric Oxide Synthase Type III / deficiency, genetics
Phenylbutyrates / pharmacology
Phenylephrine / pharmacology
Ribonucleotides / pharmacology
Taurochenodeoxycholic Acid / pharmacology
Tunicamycin / pharmacology
Vasoconstriction* / drug effects
Vasoconstrictor Agents / pharmacology
|R01 HL074399/HL/NHLBI NIH HHS; R01 HL079584/HL/NHLBI NIH HHS; R01 HL080499/HL/NHLBI NIH HHS; R01 HL089920/HL/NHLBI NIH HHS; R01 HL096032/HL/NHLBI NIH HHS; R01 HL105157/HL/NHLBI NIH HHS; R01 HL110488/HL/NHLBI NIH HHS; R01HL074399/HL/NHLBI NIH HHS; R01HL079584/HL/NHLBI NIH HHS; R01HL080499/HL/NHLBI NIH HHS; R01HL08920/HL/NHLBI NIH HHS; R01HL096032/HL/NHLBI NIH HHS; R01HL105157/HL/NHLBI NIH HHS; R01HL110488/HL/NHLBI NIH HHS|
|0/Antihypertensive Agents; 0/Enzyme Activators; 0/Leupeptins; 0/Myosin Light Chains; 0/Phenylbutyrates; 0/Ribonucleotides; 0/Vasoconstrictor Agents; 11089-65-9/Tunicamycin; 11128-99-7/Angiotensin II; 133407-82-6/benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 360-97-4/Aminoimidazole Carboxamide; 516-35-8/Taurochenodeoxycholic Acid; 59-42-7/Phenylephrine; 60EUX8MN5X/tauroursodeoxycholic acid; 7WY7YBI87E/4-phenylbutyric acid; EC 126.96.36.199/Nitric Oxide Synthase Type III; EC 188.8.131.52/Nos3 protein, mouse; EC 184.108.40.206/AMP-Activated Protein Kinases; EC 220.127.116.11/AMPK alpha2 subunit, mouse; F0X88YW0YK/AICA ribonucleotide|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Leukocyte-Specific CCL3 Deficiency Inhibits Atherosclerotic Lesion Development by Affecting Neutroph...
Next Document: Notch-Dependent Regulation of the Ischemic Vasodilatory Response--Brief Report.